Physician profile
Thomas A Judd
NPI 1487615704
$6,205.15
in general payments reported to CMS, 2019-2025
21 companies · $1,351 in 2025
The $1,351 reported for 2025 was more than what 94% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $685 · 2020: $127 · 2021: $538 · 2022: $821 · 2023: $1,204 · 2024: $1,479 · 2025: $1,351.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,035.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,034.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $1,150.26 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Amgen INC. | $626.29 | 2024-2025 | Tepezza, Tavneos |
| Horizon Therapeutics Plc | $585.49 | 2022-2023 | Tepezza, Uplizna |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $461.08 | 2019-2021 | |
| Abbvie INC. | $432.72 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $411.13 | 2023-2025 | Cequa |
| Catalyst Pharmaceuticals, INC. | $392.16 | 2022-2025 | Firdapse |
| Tarsus Pharmaceuticals, INC. | $352.76 | 2024-2025 | Xdemvy |
| Johnson & Johnson Surgical Vision, INC. | $327.04 | 2019-2022 | |
| Aerie Pharmaceuticals, INC. | $311.40 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $262.39 | 2025 | Ultomiris |
| Allergan, INC. | $252.33 | 2019-2021 | |
| Alcon Vision LLC | $197.28 | 2021-2025 | Rocklatan, Tryptyr |
| Mallinckrodt Hospital Products INC. | $116.11 | 2022-2025 | Acthar |
| Novartis Pharmaceuticals Corporation | $74.35 | 2022-2023 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Notal Vision, INC. | $68.87 | 2024 | Foresee Home |
| Dompe US, INC. | $48.40 | 2024-2025 | Oxervate |
| Harrow Eye, LLC | $45.00 | 2025 | Vevye |
| Kala Pharmaceuticals, INC. | $44.82 | 2021-2022 | |
| Rayner Intraocular Lenses Limited | $27.96 | 2025 | Omidria |
| Shire North American Group INC | $17.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Judd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.